Research Radartracking 1,138 published studies · 277 human · 6 safety signals · 42 clinical trials · 44 cancer pages · updated Jul 2026Open the Research Map →
Niraparib †Rx
Rx PARP i: Catalytic ↓ + trapping ↑ → HRD lethality; phase III PFS gains in ovarian/breast/prostate/endometrial.
Educational only, not medical advice. OncoForge makes no claim that Niraparib †Rx treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.
Key Takeaway
Oral PARP1/2 inhibitor with clinically proven maintenance and treatment benefits in HRD/BRCA-altered tumors—most robust in ovarian cancer—by blocking PARP repair and trapping PARP on DNA to exploit synthetic lethality.
Evidence at a glance
Tier 5OvarianBreastProstateEndometrial
FDA/EMA-approved for ovarian maintenance (PRIMA, NORA); phase III in prostate (MAGNITUDE); meta-PFS HR 0.45 in HRD+; real-world PSA responses in mCRPC; ongoing in endometrial/breast.
Niraparib inhibits PARP catalytic activity and traps PARP-DNA complexes, stalling replication forks and converting single-strand lesions into double-strand breaks. HRD/BRCA-deficient cells cannot repair these DSBs by homologous recombination → apoptosis. Phase III trials show significant PFS gains in ovarian cancer (including all-comer maintenance with strongest effect in HRD-positive subgroups). Combination strategies (e.g., with bevacizumab) and expansion to other HRR-deficient tumors are supported by growing evidence.
Targets & pathways
Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.
Combinations reported in the literature, not a protocol or a recommendation.
Bevacizumab: PFS HR 0.43 in ovarian PAOLA-1 combo.
Pembrolizumab: ORR 30% in HRD endometrial phase II.
Curcumin: Preclinical PARP/ROS synergy in ovarian models.
Resveratrol: Enhanced HRD kill in breast cancer lines.
Overlapping mechanisms
PARP: Cross-resistance with olaparib/talazoparib; switch class if progression.
HRD Lethality: Redundant in BRCA+; monitor for MDS/AML with sequential use.
Safety & interactions
Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.
What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination — a gap, not evidence of no effect. Open a row to see its studies.
CancerHuman evidenceMechanismSafetyTrial
Advanced Or Metastatic High Grade Epithelial Ovarian Cancer—1—1
This paper is an expert consensus, not a clinical study of a single drug. Eleven specialists reviewed the literature and issued recommendations for managing advanced or metastatic high-grade epithelial ovarian cancer, including surgery, chemotherapy, genetic testing, bevacizumab, and PARP inhibitors. It does not report new patient outcomes from a trial. The document mainly summarizes what the panel suggested based on existing guidelines and evidence.
The panel suggested primary cytoreductive surgery as the initial approach when complete resection is feasible.
Neoadjuvant chemotherapy followed by interval surgery was suggested when complete cytoreduction is unlikely or the patient has poor functional status/comorbidities.
Bevacizumab was suggested with platinum-based chemotherapy for high-risk disease, with maintenance only if it was part of first-line therapy.
PARP inhibitors (olaparib, niraparib, rucaparib) were suggested as maintenance in selected BRCA/HRD-defined groups.
For platinum-resistant relapse, sequential non-platinum single-agent chemotherapy and best supportive care for poor performance status were suggested.
Limitations: This is a consensus statement/practice guideline, not an original comparative trial.; No new efficacy or safety data are reported in the abstract.; Recommendations are based on literature review and expert agreement, so they are subject to guideline-selection and expert-opinion bias.; The abstract does not provide patient-level outcomes, follow-up, or effect estimates.; Several recommendations are conditional/suggested rather than based on direct evidence from this paper..
Provides management recommendations for advanced/metastatic epithelial ovarian cancer, including several anticancer agents and maintenance strategies.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Case reportReported positiveLimited evidenceTier 3 · early humann = 1
This is a case report of a 61-year-old woman with stage IIIC ovarian carcinosarcoma who underwent extensive cytoreductive surgery followed by six cycles of carboplatin, paclitaxel and bevacizumab. Bevacizumab was not continued after chemotherapy because of severe myelosuppression and cost; the patient then received oral niraparib maintenance. At 6 months after the sixth chemotherapy, CA-125 fell to 4.55 U/ml and imaging plus tumor marker assessment indicated remission at short-term follow-up. The report suggests combined surgery, chemotherapy and targeted maintenance was associated with a favorable short-term outcome in this single patient.
Reported effects: number_of_chemotherapy_cycles 6, n=1 · CA-125 at 6 months 4.55, n=1 · +1 more
Extensive cytoreductive surgery performed (sub-extensive hysterectomy, bilateral adnexectomy, sigmoid colon and partial rectal resection, lymph node dissection).
Postoperative pathology confirmed ovarian carcinosarcoma with serous carcinoma and squamous carcinoma components; sarcomatous elements included fibrosarcoma, chondrosarcoma and rhabdomyosarcoma.
Patient staged as FIGO IIIC and TNM T3cN1M0.
The patient received six cycles of carboplatin, paclitaxel plus bevacizumab.
Severe myelosuppression occurred during and after chemotherapy; bevacizumab was not maintained after chemotherapy (also noted to be expensive).
Following chemotherapy the patient received oral niraparib maintenance therapy.
At 6 months after the sixth chemotherapy, cancer antigen 125 levels dropped to 4.55 U/ml (within normal range).
Short-term 6-month follow-up by ultrasonography, CT, MRI and serum tumor markers indicated a remission prognosis.
Limitations: Single-patient case report — results not generalizable.; Short follow-up duration (6 months) — no long-term outcomes reported.; No control or comparator group to attribute benefit to any specific component of the management.; Bevacizumab was discontinued (and had toxicity/cost issues), complicating interpretation of the combined regimen's effect.; No dose details provided for niraparib or chemotherapeutic agents..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
What changed recently
The latest additions to Niraparib †Rx's evidence base, and anything that's been retracted.
Cancers where Niraparib †Rx reported positive results
Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.
Limitations: Single-patient case report — results not generalizable.; Short follow-up duration (6 months) — no long-term outcomes reported.; No control or comparator group to attribute benefit to any specific component of the management.; Bevacizumab was discontinued (and had toxicity/cost issues), complicating interpretation of the combined regimen's effect.; No dose details provided for niraparib or chemotherapeutic agents..
A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.
No human studies yet · No numeric effect sizes reported · Based on a single study.
Dose: as studied, not a recommendation
These are doses as studied or reported, never a recommendation. The right amount of Niraparib †Rx depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.
Ranges seen in adjunct / practice use: 200–300 mg/day (po) QD continuous; individualized (e.g., 200 mg if platelets <150k), Maintenance 300 mg QD; reduce to 200 mg for toxicity; no food effect but consistent timing..
6 ongoing · 8 completed · tracked from ClinicalTrials.gov. Recruiting is not the same as proven, and completed is not the same as positive — read the results. Not a recommendation.
Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.